August 2012
-
GSK and Theravance have announced that the European Commission has approved Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of asthma for patients whose disease is not adequately controlled by ICS plus an as-needed… Read more . . .
-
Intertek, which recently acquired Melbourn Scientific, has announced the launch of development, formulation and characterization service for both large and small molecule inhaled and nasal drug products. The acquisition of Melbourn Scientific was announced in… Read more . . .
-
Express Scripts, a pharmacy benefit manager (PBM) that administers prescription drug programs for more than 100 million Americans, has announced the exclusion of more than a dozen popular OINDPs from its 2014 national preferred drug… Read more . . .
-
The United States Patent and Trademark Office (USPTO) has issued Civitas Therapeutics US Patent No. 8,545,878, with an expiration date of November 16, 2032, for a patent titled “Capsules containing high doses of levodopa for… Read more . . .
-
Bend Research has announced a $20+ million expansion of its commercial spray drying capacity, including a new commercial manufacturing facility with two PSD spray dryer process trains. The company expects completion and validation of the… Read more . . .
-
In a November 5, 2013 interview on CNBC, Acorda CEO Ron Cohen announced that the company has filed a regulatory application to the FDA for its diazepam nasal spray for the treatment of epilepsy. Acorda… Read more . . .
-
Novartis has announced that “it will initiate consultation on proposals to close” its respiratory R&D center in Horsham, UK. According to Novartis, the potential closing will affect “up to 371 roles” at the site, plus… Read more . . .
-
The US FDA has issued a warning letter to Sunovion regarding claims made in four patient brochures aimed respectively at COPD patients currently using MDIs, DPIs, nebulized short acting beta agonists, or any medication giving… Read more . . .
-
Copley Scientific‘s new TPK-R critical flow controller is designed specifically to connect to the right-hand outlet of NGI cascade impactor, allowing for efficient use of bench space, the company says. The TPK-R is a mirror… Read more . . .
-
Health Canada has approved Almirall’s Tudorza Genuair aclidinium bromide DPI for the treatment of COPD, Almirall Canada has announced. Forest Laboratories is partnered with Almirall on commercialization of the product in Canada and in the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland